Levetiracetam Viatris

Levetiracetam, the active ingredient in Levetiracetam Viatris, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for adjunctive therapy in various seizure types and is prescribed for patients with epilepsy who require additional seizure control. GNH USA supplies Levetiracetam Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug used to manage seizure disorders. It is employed as an adjunctive therapy in the following conditions: - Partial‑onset seizures: reduces the frequency of focal seizures when added to existing therapy. - Generalized tonic‑clonic seizures: helps control convulsive seizures in patients with refractory epilepsy. - Myoclonic seizures: diminishes myoclonic jerks as part of combination treatment.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: generalized tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: occasional stomach upset. - Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood disorders: depression, suicidal thoughts, or severe anxiety. - Hematologic abnormalities: low blood cell counts. - Liver enzyme elevation: signs of hepatic stress. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Multiorgan hypersensitivity: systemic involvement requiring urgent care.

When prescribing Levetiracetam, clinicians should consider several safety aspects. - Renal function: adjust dose in patients with impaired clearance. - Pregnancy: Category B, use only if benefits outweigh risks. - Breastfeeding: monitor infant for sedation or irritability. - Psychiatric history: observe for mood changes or suicidal ideation. - Concomitant CNS depressants: assess for additive sedation. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Levetiracetam has a relatively low potential for drug‑drug interactions, but certain combinations require attention.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: can lower levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam exposure. - Topiramate: additive CNS side effects such as dizziness. - Alcohol: enhanced sedation and impairment. - Other antiepileptics: monitor overall seizure control and side‑effect profile.